InTest Corporation announced a $3.7 million follow‑on order from an existing medical‑device manufacturer on December 9, 2025. The order will be fulfilled by Alfamation, InTest’s functional‑test systems business, and will supply conveyor‑based test systems capable of automating high‑volume testing of up to 50 million devices per year. The new contract expands InTest’s presence in the life‑sciences market and reinforces its strategy to diversify beyond its traditional semiconductor focus.
The order is a sizable addition to InTest’s growing order book in high‑value sectors such as automotive/EV, defense/aerospace, and industrial. In the third quarter of 2025, the company reported revenue of $26.2 million, missing analyst estimates, and an adjusted net loss of $0.02 per share. Orders surged to $37.6 million and the backlog grew to $49.3 million, indicating strong future demand. The $3.7 million order represents roughly 14 % of the company’s quarterly revenue and 10 % of its Q3 order book, underscoring its material impact.
Alfamation’s CEO, Mauro Arigossi, highlighted the order’s significance, noting that the systems “demonstrate our expertise in conducting high‑performance electrical measurements by performing functional tests at the PCB level—a crucial capability for products that cannot be evaluated when fully assembled.” The ability to test devices at the PCB level is especially valuable in the medical‑device sector, where regulatory compliance and safety are paramount.
InTest has faced revenue headwinds in the past twelve months, with a 3.58 % decline in revenue and a loss of profitability. The company’s VISION 2030 plan, launched in March 2025, targets revenue between $235 million and $285 million by 2030. The new order supports this goal by adding a stable, high‑margin revenue stream in a sector that is less cyclical than semiconductors, thereby improving the company’s risk profile and long‑term growth prospects.
The order also signals confidence from a key customer, reinforcing InTest’s track record of securing repeat business in the life‑sciences market. By expanding its product portfolio to include high‑volume testing solutions for medical devices, InTest is positioning itself to capture a share of the growing demand for rapid, automated testing in regulated industries. This diversification is expected to help the company weather semiconductor market volatility and accelerate its transition toward a more balanced revenue mix.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.